Determination and comparison of incidence rate and trend ofmorbidity of leukemia and lymphoma in Mazandaran province (1376-1382)

Abstract

Background and purpose: Malignancies are the second most important cause of mortality in many countries. Leukemia and lymphoma happen with significantly high incidence rates throughout the world particularly in Iran where it causes remarkable mortality as well as high diagnosis and treatment expenditures for both families and health system. Leukemia and lymphoma totally include about 11 percent of cancers in Mazandaran province. The purpose of this study was a general and specific description of leukemia and lymphoma in Mazandaran province.Materials and Methods: In this study, the medical records of all patients with certain diagnosis of leukemia and lymphoma along with valid laboratory or pathology reports were reviewed from 1376-1382. Data collection was undertaken by Babol health research center affiliated to Tehran University Medical Sciences. This research consists of cross-sectional, descriptive and analytic studies and examines variables including: age, sex, city of inhabitation, year of incidence and type of malignancy. The incidence rates in 100,000 persons of related population have been calculated and analyzed.Results: In Mazandaran province, 1146 cases of leukemia (lymphoidic and myeloidic) and lymphoma (Hodgkin's and non Hodgkin's) were diagnosed from 1376-1382. an average of 5.9 leukemia and lymphoma cases per 100,000 occure annually. The highest incidence rates were obtained at age of 70 or above (26.4) and the least at age of 0-9 (2.26).The incidence rates in males and females were 7.05 and 4.76 respectively and the male to female incidence rate was 1.48. The highest incidence rate was observed in Babol (7.29) and the least was equally calculated in Neka and Tonekabon (1.47). The highest and lowest incidence were obtained in 1380 (7.75) and 1377 (3.15) respectively. Regarding the type of malignancy, non Hodgkin lymphoma, 2.53 in 100000 persons, was the most prevalent and myeloidic leukemia, 1.07 in 100000 persons, the least prevalent cases.